What is Lucid Diagnostics's stock-based comp?

Lucid Diagnostics (LUCD) reported stock-based comp of $1.14M in Q3 2025.

How has Lucid Diagnostics's stock-based comp changed year-over-year?

Lucid Diagnostics's stock-based comp decreased by 4.1% year-over-year, from $1.18M to $1.14M.

What is the long-term trend for Lucid Diagnostics's stock-based comp?

Over 2 years (2022 to 2024), Lucid Diagnostics's stock-based comp has grown at a -45.1% compound annual growth rate (CAGR), from $13.86M to $4.18M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Lucid Diagnostics LUCD Stock-Based Comp

Stock-Based Comp at other companies

Castle BiosciencesCSTL

$9.78M-12.6%

Guardant HealthGH

$47.61M+26.1%

Biodesix, Inc.BDSX

$1.12M+14.7%

Insight Molecular Diagnostics Inc. Common StockIMDX

$615K+30.0%

Fulgent Genetics, Inc.FLGT

$9.89M-6.3%

Personalis, Inc.PSNL

$2.55M+15.1%

Other financials

Income statement

See full

Revenue$1.3M+51.7%

Gross profit-$369.0K+49.0%

Operating income-$12.1M+3.0%

Net income-$13.9M+48.3%

EPS (diluted)-$0.10+60.0%

Balance sheet

See full

Cash & equivalents$27.9M+10.6%

Total debt$1.6M-35.1%

Total equity$4.0M+174%

Total assets$34.1M+3.9%

Cash flow

See full

Operating cash flow-$12.1M+2.9%

CapEx$215.0K+131%

Free cash flow-$12.3M+1.9%

Valuation

See full

Market cap$204.13M+58.5%

Enterprise value$177.85M+78.0%

P/S39.8×+10.2×

Profitability

See full

Gross margin-66.8%—

Operating margin-959.6%-133pp

Net margin-876.7%-254pp

FCF margin-1,099.6%—

Returns & leverage

See full

Return on equity-710.6%—

Debt / equity0.4×—

Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Lucid Diagnostics’s 10-Q, filed November 12, 2025, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lucid Diagnostics's stock-based comp?: Lucid Diagnostics (LUCD) reported stock-based comp of $1.14M in Q3 2025.
How has Lucid Diagnostics's stock-based comp changed year-over-year?: Lucid Diagnostics's stock-based comp decreased by 4.1% year-over-year, from $1.18M to $1.14M.
What is the long-term trend for Lucid Diagnostics's stock-based comp?: Over 2 years (2022 to 2024), Lucid Diagnostics's stock-based comp has grown at a -45.1% compound annual growth rate (CAGR), from $13.86M to $4.18M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.